메뉴 건너뛰기




Volumn 36, Issue 4, 2011, Pages 344-350

Meta-analysis of dermatological toxicities associated with sorafenib

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

EID: 79955960147     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04060.x     Document Type: Review
Times cited : (56)

References (36)
  • 1
    • 4944249117 scopus 로고    scopus 로고
    • BAY43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis
    • Wilhelm SM, Carter C, Tang L et al. BAY43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
    • (2004) Cancer Res , vol.64 , pp. 7099-7109
    • Wilhelm, S.M.1    Carter, C.2    Tang, L.3
  • 2
    • 79955974210 scopus 로고    scopus 로고
    • US Food and Drug Administration. Nexavar (sorafenib) prescribing information. Available at: (accessed 10 June 2010).
    • US Food and Drug Administration. Nexavar (sorafenib) prescribing information. Available at: (accessed 10 June 2010).
  • 3
    • 33744984843 scopus 로고    scopus 로고
    • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
    • Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.
    • (2006) J Clin Oncol , vol.24 , pp. 2505-2512
    • Ratain, M.J.1    Eisen, T.2    Stadler, W.M.3
  • 4
    • 70249097380 scopus 로고    scopus 로고
    • Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    • Escudier B, Eisen T, Stadler WM et al. Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-18.
    • (2009) J Clin Oncol , vol.27 , pp. 3312-3318
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 5
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 6
    • 33748325763 scopus 로고    scopus 로고
    • Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis
    • Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95: 581-6.
    • (2006) Br J Cancer , vol.95 , pp. 581-586
    • Eisen, T.1    Ahmad, T.2    Flaherty, K.T.3
  • 7
    • 70149124507 scopus 로고    scopus 로고
    • Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group
    • Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115: 4090-5.
    • (2009) Cancer , vol.115 , pp. 4090-4095
    • Dreicer, R.1    Li, H.2    Stein, M.3
  • 8
    • 70149087258 scopus 로고    scopus 로고
    • Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
    • Bianchi G, Loibl S, Zamagni C et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009; 20: 616-24.
    • (2009) Anticancer Drugs , vol.20 , pp. 616-624
    • Bianchi, G.1    Loibl, S.2    Zamagni, C.3
  • 9
    • 67149130074 scopus 로고    scopus 로고
    • Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
    • Aragon-Ching JB, Jain L, Gulley JL et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103: 1636-40.
    • (2009) BJU Int , vol.103 , pp. 1636-1640
    • Aragon-Ching, J.B.1    Jain, L.2    Gulley, J.L.3
  • 10
    • 50649095250 scopus 로고    scopus 로고
    • Phase II trial of sorafenib in advanced thyroid cancer
    • Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-19.
    • (2008) J Clin Oncol , vol.26 , pp. 4714-4719
    • Gupta-Abramson, V.1    Troxel, A.B.2    Nellore, A.3
  • 11
    • 34548504810 scopus 로고    scopus 로고
    • Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
    • Elser C, Siu LL, Winquist E et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73.
    • (2007) J Clin Oncol , vol.25 , pp. 3766-3773
    • Elser, C.1    Siu, L.L.2    Winquist, E.3
  • 12
    • 65349161533 scopus 로고    scopus 로고
    • A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens
    • abstract).
    • Schiller JH, Lee JW, Hanna NH et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens. J Clin Oncol 2008; 26 (Suppl.): 8014 (abstract).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.. , pp. 8014
    • Schiller, J.H.1    Lee, J.W.2    Hanna, N.H.3
  • 13
    • 59949103514 scopus 로고    scopus 로고
    • Sorafenib (SOR) is active in patients with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase ll trial of the University of Chicago Phase ll Consortium
    • abstract).
    • Wiebe L, Kasza K, Maki RG et al. Sorafenib (SOR) is active in patients with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase ll trial of the University of Chicago Phase ll Consortium. J Clin Oncol 2008; 26 (Suppl.): 10502 (abstract).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.. , pp. 10502
    • Wiebe, L.1    Kasza, K.2    Maki, R.G.3
  • 14
    • 33748913369 scopus 로고    scopus 로고
    • Phase II trial of single agent sorafenib in patients with advanced non-small cell lung carcinoma
    • abstract).
    • Gatzemeier U, Blumenschein G, Fosella F et al. Phase II trial of single agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2008; 26 (Suppl.): 7002 (abstract).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.. , pp. 7002
    • Gatzemeier, U.1    Blumenschein, G.2    Fosella, F.3
  • 15
    • 62449186539 scopus 로고    scopus 로고
    • Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma
    • Escudier B, Szczylik C, Hutson TE et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280-9.
    • (2009) J Clin Oncol , vol.27 , pp. 1280-1289
    • Escudier, B.1    Szczylik, C.2    Hutson, T.E.3
  • 16
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    • Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.L.1    Kang, Y.K.2    Chen, Z.3
  • 17
    • 73749087933 scopus 로고    scopus 로고
    • Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer
    • Di Lorenzo G, Cartenì G, Autorino R et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009; 27: 4469-74.
    • (2009) J Clin Oncol , vol.27 , pp. 4469-4474
    • Di Lorenzo, G.1    Cartenì, G.2    Autorino, R.3
  • 18
    • 67650293850 scopus 로고    scopus 로고
    • Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    • Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-40.
    • (2009) J Clin Oncol , vol.27 , pp. 3133-3140
    • Maki, R.G.1    D'Adamo, D.R.2    Keohan, M.L.3
  • 19
    • 59449089100 scopus 로고    scopus 로고
    • Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response
    • Yau T, Chan P, Ng KK et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-36.
    • (2009) Cancer , vol.115 , pp. 428-436
    • Yau, T.1    Chan, P.2    Ng, K.K.3
  • 20
    • 58149335533 scopus 로고    scopus 로고
    • Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
    • Moreno-Aspitia A, Morton RF, Hillman DW et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009; 27: 11-15.
    • (2009) J Clin Oncol , vol.27 , pp. 11-15
    • Moreno-Aspitia, A.1    Morton, R.F.2    Hillman, D.W.3
  • 21
    • 40749122148 scopus 로고    scopus 로고
    • A phase II clinical trial of sorafenib in androgen-independent prostate cancer
    • Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209-14.
    • (2008) Clin Cancer Res , vol.14 , pp. 209-214
    • Dahut, W.L.1    Scripture, C.2    Posadas, E.3
  • 22
    • 36249017922 scopus 로고    scopus 로고
    • Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
    • Akaza H, Tsukamoto T, Murai M et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755-62.
    • (2007) Jpn J Clin Oncol , vol.37 , pp. 755-762
    • Akaza, H.1    Tsukamoto, T.2    Murai, M.3
  • 23
    • 33749017926 scopus 로고    scopus 로고
    • Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    • Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
    • (2006) J Clin Oncol , vol.24 , pp. 4293-4300
    • Abou-Alfa, G.K.1    Schwartz, L.2    Ricci, S.3
  • 24
    • 34648863567 scopus 로고    scopus 로고
    • The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy
    • abstract).
    • Knox JJ, Figlin R, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007; 25 (Suppl. 18): 5011 (abstract).
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL.. 18 , pp. 5011
    • Knox, J.J.1    Figlin, R.2    Stadler, W.M.3
  • 25
    • 37349126289 scopus 로고    scopus 로고
    • Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060)
    • abstract).
    • D'Adamo DR, Keohan M, Schuetze S et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). J Clin Oncol 2007; 25 (Suppl. 18): 10001 (abstract).
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL.. 18 , pp. 10001
    • D'Adamo, D.R.1    Keohan, M.2    Schuetze, S.3
  • 26
    • 41349094931 scopus 로고    scopus 로고
    • MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumours (NET): a Phase II consortium (P2C) study
    • abstract).
    • Hobday TJ, Holen K, Picus J et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumours (NET): a Phase II consortium (P2C) study. J Clin Oncol 2007; 25 (Suppl. 18): 4004 (abstract).
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL.. 18 , pp. 4004
    • Hobday, T.J.1    Holen, K.2    Picus, J.3
  • 27
    • 38349030422 scopus 로고    scopus 로고
    • Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
    • Porta C, Paglino C, Imarisio I et al. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007; 7: 127-34.
    • (2007) Clin Exp Med , vol.7 , pp. 127-134
    • Porta, C.1    Paglino, C.2    Imarisio, I.3
  • 28
    • 0034231616 scopus 로고    scopus 로고
    • Antineoplastic therapy-induced palmar plantar erythrodysesthesia (hand-foot) syndrome: incidence, recognition and management
    • Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (hand-foot) syndrome: incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-34.
    • (2000) Am J Clin Dermatol , vol.1 , pp. 225-234
    • Nagore, E.1    Insa, A.2    Sanmartin, O.3
  • 29
    • 58149345018 scopus 로고    scopus 로고
    • Dermatologic symptoms associated with the multikinase inhibitor sorafenib
    • Robert C, Mateus C, Spatz A et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60: 299-305.
    • (2009) J Am Acad Dermatol , vol.60 , pp. 299-305
    • Robert, C.1    Mateus, C.2    Spatz, A.3
  • 30
    • 33846924560 scopus 로고    scopus 로고
    • Hand-foot and stump syndrome to sorafenib
    • Lai SKT, Lacouture M. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007; 25: 341.
    • (2007) J Clin Oncol , vol.25 , pp. 341
    • Lai, S.K.T.1    Lacouture, M.2
  • 31
    • 52949138886 scopus 로고    scopus 로고
    • Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
    • Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19: 1955-61.
    • (2008) Ann Oncol , vol.19 , pp. 1955-1961
    • Lacouture, M.E.1    Reilly, L.M.2    Gerami, P.3
  • 32
    • 34247361171 scopus 로고    scopus 로고
    • Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma
    • Tsai KY, Yang CH, Kuo TT et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 24: 5786-8.
    • (2006) J Clin Oncol , vol.24 , pp. 5786-5788
    • Tsai, K.Y.1    Yang, C.H.2    Kuo, T.T.3
  • 33
    • 0028293816 scopus 로고
    • Expression of c-kit ligand in human keratinocytes
    • Morita E, Lee DG, Sugiyama M et al. Expression of c-kit ligand in human keratinocytes. Arch Dermatol Res 1994; 286: 273-7.
    • (1994) Arch Dermatol Res , vol.286 , pp. 273-277
    • Morita, E.1    Lee, D.G.2    Sugiyama, M.3
  • 34
    • 21344462378 scopus 로고    scopus 로고
    • Cutaneous side-effects of kinase inhibitors and blocking antibodies
    • Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
    • (2005) Lancet Oncol , vol.6 , pp. 491-500
    • Robert, C.1    Soria, J.C.2    Spatz, A.3
  • 35
    • 71949112710 scopus 로고    scopus 로고
    • Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
    • Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-51.
    • (2009) Br J Dermatol , vol.161 , pp. 1045-1051
    • Lee, W.J.1    Lee, J.L.2    Chang, S.E.3
  • 36
    • 77949517580 scopus 로고    scopus 로고
    • Management of vascular endothelial growth factor and multikinase inhibitor side effects
    • Wood LS. Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clin J Oncol Nurs 2009; 13 (Suppl.): 13-18.
    • (2009) Clin J Oncol Nurs , vol.13 , Issue.SUPPL.. , pp. 13-18
    • Wood, L.S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.